Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02098512
Title Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors New York Medical College

Hodgkin's lymphoma


Brentuximab vedotin

Age Groups: child | adult
Covered Countries USA

No variant requirements are available.